FR2896881B1 - Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie - Google Patents

Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Info

Publication number
FR2896881B1
FR2896881B1 FR0600851A FR0600851A FR2896881B1 FR 2896881 B1 FR2896881 B1 FR 2896881B1 FR 0600851 A FR0600851 A FR 0600851A FR 0600851 A FR0600851 A FR 0600851A FR 2896881 B1 FR2896881 B1 FR 2896881B1
Authority
FR
France
Prior art keywords
prongf
therapy
determining
breast cancer
vitro diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0600851A
Other languages
English (en)
French (fr)
Other versions
FR2896881A1 (fr
Inventor
Kastylevsky Genevieve Choquet
Yohan Demont
Hubert Hondermarck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Universite Lille 1 Sciences et Technologies
Original Assignee
Biomerieux SA
Universite Lille 1 Sciences et Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0600851A priority Critical patent/FR2896881B1/fr
Application filed by Biomerieux SA, Universite Lille 1 Sciences et Technologies filed Critical Biomerieux SA
Priority to ES07731536.4T priority patent/ES2471126T3/es
Priority to PCT/FR2007/050708 priority patent/WO2007088305A1/fr
Priority to CN2007800040238A priority patent/CN101395478B/zh
Priority to JP2008552858A priority patent/JP5091876B2/ja
Priority to EP07731536.4A priority patent/EP1982192B1/fr
Priority to CN2013103889291A priority patent/CN103446585A/zh
Priority to US12/087,606 priority patent/US8008009B2/en
Publication of FR2896881A1 publication Critical patent/FR2896881A1/fr
Application granted granted Critical
Publication of FR2896881B1 publication Critical patent/FR2896881B1/fr
Priority to US13/137,101 priority patent/US20110293636A1/en
Priority to JP2012124525A priority patent/JP5792121B2/ja
Priority to US13/533,908 priority patent/US9061045B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
FR0600851A 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie Expired - Fee Related FR2896881B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
US12/087,606 US8008009B2 (en) 2006-01-31 2007-01-30 Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF
CN2007800040238A CN101395478B (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途
JP2008552858A JP5091876B2 (ja) 2006-01-31 2007-01-30 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
EP07731536.4A EP1982192B1 (fr) 2006-01-31 2007-01-30 PROCEDE DE DOSAGE DU ProNGF POUR LE DIAGNOSTIC IN VITRO DU CANCER EN PARTICULIER DU CANCER DU SEIN, DE LA THYROIDE, de la prostate, OU DU POUMON ET UTILISATION DU PRONGF EN THERAPIE
CN2013103889291A CN103446585A (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途
ES07731536.4T ES2471126T3 (es) 2006-01-31 2007-01-30 Procedimiento de ensayo del ProNGF para el diagnóstico in vitro del cáncer, en particular del cáncer de mama, de tiroides, de la pr�stata o de pulmón, y utilización del proNGF en terapia
PCT/FR2007/050708 WO2007088305A1 (fr) 2006-01-31 2007-01-30 Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie
US13/137,101 US20110293636A1 (en) 2006-01-31 2011-07-20 Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf
JP2012124525A JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
US13/533,908 US9061045B2 (en) 2006-01-31 2012-06-26 Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Publications (2)

Publication Number Publication Date
FR2896881A1 FR2896881A1 (fr) 2007-08-03
FR2896881B1 true FR2896881B1 (fr) 2008-04-18

Family

ID=36741378

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0600851A Expired - Fee Related FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Country Status (7)

Country Link
US (3) US8008009B2 (enExample)
EP (1) EP1982192B1 (enExample)
JP (2) JP5091876B2 (enExample)
CN (2) CN101395478B (enExample)
ES (1) ES2471126T3 (enExample)
FR (1) FR2896881B1 (enExample)
WO (1) WO2007088305A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
FR2944019B1 (fr) * 2009-04-03 2011-04-22 Biomerieux Sa Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CN101782585A (zh) * 2010-02-10 2010-07-21 广州医学院 肺癌组织蛋白印迹膜片及其制备方法
WO2011159762A1 (en) * 2010-06-15 2011-12-22 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP2014521958A (ja) * 2011-07-28 2014-08-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
CN103122390B (zh) * 2013-03-07 2015-04-08 上海市疾病预防控制中心 Frat1基因作为检测甲状腺癌的血清标志物及其应用
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN103866039B (zh) * 2014-04-04 2015-05-27 厦门大学 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP2977759B1 (en) * 2014-07-25 2017-07-12 Serum Institute of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
CA3051488A1 (en) * 2017-01-24 2018-08-02 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
EP3635399B1 (fr) * 2017-06-08 2025-10-29 Gnaho, Sylvain Méthode d'isolement et de détection de cellules souches cancéreuses
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
WO2003076942A2 (fr) 2002-03-13 2003-09-18 Biomerieux Quantification de cellules tumorales circulantes issues de cancers solides
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
ATE545429T1 (de) * 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Also Published As

Publication number Publication date
CN101395478B (zh) 2013-08-28
JP5792121B2 (ja) 2015-10-07
JP5091876B2 (ja) 2012-12-05
JP2009525478A (ja) 2009-07-09
US9061045B2 (en) 2015-06-23
WO2007088305A1 (fr) 2007-08-09
CN101395478A (zh) 2009-03-25
US20090068200A1 (en) 2009-03-12
EP1982192B1 (fr) 2014-03-26
FR2896881A1 (fr) 2007-08-03
US20110293636A1 (en) 2011-12-01
EP1982192A1 (fr) 2008-10-22
US20130171173A1 (en) 2013-07-04
ES2471126T3 (es) 2014-06-25
JP2012211148A (ja) 2012-11-01
CN103446585A (zh) 2013-12-18
US8008009B2 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
FR2896881B1 (fr) Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
FR2919065B1 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
EP2004230A4 (en) N-CADHERINE AND LY6 E: OBJECTIVES FOR CANCER DIAGNOSIS AND THERAPY
FR23C1027I1 (fr) Régime de traitement à l'aide de nératinib pour le cancer du sein
FR2906808B1 (fr) Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
FR2919060B1 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
EP2184997A4 (en) DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
GB0909829D0 (en) Thermomastographic apparatus for differentiation for detecting breast pathology in women and use of the thermomastographic apparatus for differentiation
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
EP2056808A4 (en) Small molecule potentiator of hormonal therapy for breast cancer
EP1869222A4 (en) METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2059210A4 (en) THERAPEUTIC DEVICES FOR TREATING VARIOUS WOMEN'S DRESS
EP1968648A4 (en) DIAGNOSIS SYSTEM FOR THE DETECTION AND DIAGNOSIS OF SKIN CANCER
EP2216344A4 (en) DIAGNOSIS AND TREATMENT OF CANCER WITH AN ANTI-GPR49 ANTIBODY
EP2303918A4 (en) METHOD FOR DOSED ADMINISTRATION OF A ACTIVIN ACTRIIA ANTAGONIST AND OBSERVATION OF TREATED PATIENTS
EP2331711A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER AND DETERMINATION OF THE TOTAL AND NON-DISABLED SURVIVAL PERIOD OF CANCER PATIENTS
IL177876A0 (en) In vitro test system for predicting patient tolerability of therapeutic agents
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
EP2744917A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER
FR2973250B1 (fr) Sonde de therapie pour le traitement de tissus par l'intermediaire d'ondes ultrasonores focalisees croisees
FR2944019B1 (fr) Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EP2200548A4 (en) FLUID FLOW DEVICE AND METHOD FOR DIAGNOSING OR THERAPY OF TISSUE
EP2094866A4 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20160930